Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10064674.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia. Current treatments of patients with SCFN-related hypercalcemia are often only partially successful and may be associated with prolonged hypercalcemia. We now report the use of etidronate, a bisphosphonate, to control hypercalcemia in an infant with SCFN.
Medical subject headings
- Etidronic Acid
- Fat Necrosis
- Hypercalcemia